Navitoclax, a novel BH3 mimetic compound, is currently under early phase clinical investigation in EGFR-mutation positive NSCLC patients who relapsed on previous EGFR TKI therapy (CilicalTrials.gov identifier NCT02520778). Here, EGFR is linked to non-small cell lung carcinoma.